| FORM 990, PART III, LINE 1 |
ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - LIFELONG LEARNING FOR ONCOLOGY PROFESSIONALS, - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCE CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. |
| FORM 990, PART III, LINE 4A |
EDUCATIONAL AND SCIENTIFIC MEETINGS AND PRODUCTS: ASCO PROVIDES EDUCATIONAL AND SCIENTIFIC PROGRAMS AND CONTENT ON A VARIETY OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON CUTTING EDGE RESEARCH AND SCIENCE IN THE FIELD OF CLINICAL ONCOLOGY. THE SCIENTIFIC RESEARCH AND EDUCATION PRESENTED AT THE MEETINGS ENHANCES KNOWLEDGE ABOUT CANCER, THUS ADVANCING HIGH-QUALITY CANCER CARE. THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER EDUCATIONAL AND SCIENTIFIC MEETING IN THE ONCOLOGY COMMUNITY AND THE THEMATIC MEETINGS PRESENTED OR CO-SPONSORED BY ASCO PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC PROGRAMMING ON SPECIFIC TYPES OF CANCERS. ASCO'S EDUCATIONAL AND SCIENTIFIC PROGRAMS SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE AND ASSIST THEM IN PROVIDING WORLD CLASS CANCER CARE AND IN CONDUCTING CUTTING EDGE RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. APPROPRIATE PROGRAMS ARE PROVIDED FOR ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, AND OTHERS TO MEET THE CHANGING NEEDS OF PEOPLE LIVING WITH CANCER AND ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS, IMPLEMENTS AND EVALUATES CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS SO THAT THEY ARE BETTER PREPARED TO MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY,ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT AVAILABLE TO THE GENERAL PUBLIC THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES EDUCATIONAL AND SCIENTIFIC MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2017 ACTIVITIES INCLUDE: OVER 39,000 PEOPLE ATTENDED THE 2017 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES,CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. APPROXIMATELY 40% OF THE ATTENDEES AT THE 2017 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2017 ANNUAL MEETING FEATURED OVER 265 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 3,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORED OR CO-SPONSORED OVER 50 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE IN AND AROUND THE WORLD. THESE MEETINGS INCLUDED: - BEST OF ASCO - Palliative and Supportive Care in Oncology Symposium - QUALITY CARE SYMPOSIUM - GI CANCERS SYMPOSIUM - GU CANCERS SYMPOSIUM - CANCER SURVIVORSHIP SYMPOSIUM INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - BEST OF ASCO INTERNATIONAL - JOINT SYMPOSIA - ADVANCED CANCER COURSES - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR LIVE MEETINGS. THE DAILY NEWS PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AT THE LIVE EVENT AND ONLINE (THE ENTIRETY OF THE PRINT VERSIONS PLUS BONUS COVERAGE) TO ASCO MEMBERS AND TO THE GENERAL PUBLIC. THE DAILY NEWS PRODUCTS INCLUDE COVERAGE OF KEY EDUCATIONAL AND SCIENTIFIC SESSIONS, EDITORIALS BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND COMMENTARY AND TOPICS OF INTEREST TO INTERNATIONAL ATTENDEES AND MEMBERS. |
| FORM 990, PART III, LINE 4B |
QUALITY: ASCO develops evidence-based guidelines, develops and validates quality measures in oncology, and conducts quality improvement and measurement activities. PROGRAMS INCLUDE: - CANCERLINQ, AN INITIATIVE TO DEVELOP A RAPID LEARNING SYSTEM IN ONCOLOGY. THIS EFFORT IS INTENDED TO TRANSFORM THE WAY ONCOLOGISTS PRACTICE, LEARN, AND INTERACT WITH THEIR PATIENTS. - QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. - QOPI CERTIFICATION PROGRAM. THE QOPI CERTIFICATION PROGRAM BUILDS UPON THE SUCCESS OF QOPI. QOPI CERTIFICATION DEMONSTRATES A COMMITMENT TO EXCELLENCE AND ONGOING QUALITY IMPROVEMENT IN THE HEMATOLOGY-ONCOLOGY OUTPATIENT PRACTICE. THE GOALS OF THE QOPI CERTIFICATION PROGRAM ARE TO: - PROMOTE HIGH QUALITY CANCER CARE AS DEFINED BY THE CLINICIAN EXPERTS. - PROVIDE A TRUSTED SOLUTION TO SATISFY EXTERNAL DEMAND FOR QUALITY ACTIVITIES. - REDUCE REDUNDANT PROGRAMS OR ADMINISTRATIVE BURDENS RELATED TO THE DEMONSTRATION OF QUALITY. - NEW GUIDELINES AND ONGOING UPDATES. ASCO HAS PUBLISHED OVER 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. |
| FORM 990, PART III, LINE 4C |
EDUCATIONAL PUBLICATIONS: ASCO PUBLISHES SEVERAL EDUCATIONAL JOURNALS ADDRESSING CLINICAL ONCOLOGY THAT ARE AVAILABLE TO THE PUBLIC. JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. THE JOURNAL OF GLOBAL ONCOLOGY (JGO) IS AN ONLINE ONLY, OPEN ACCESS JOURNAL FOCUSED ON CANCER CARE, RESEARCH AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. JCO CLINICAL CANCER INFORMATICS IS AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL PUBLISHING CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION AND IMAGES. JCO PRECISION ONCOLOGY IS A PEER-REVIEWED, ONLINE-ONLY, ARTICLE BASED JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINE GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. |
| FORM 990, PART III, LINE 4D |
CANCER POLICY AND CLINICAL AFFAIRS: ASCO addresses policy issues raised in the practice of oncology, cancer research, care, and prevention by working with volunteer committees and ASCO leaders to shape policy, law and regulation of issues of importance in oncology. ASCOs policy and clinical affairs programs cover a broad spectrum of issues, including patient-oriented research, health insurance, clinical practice, workforce, disparities, cost/access, cancer survivorship, and cancer prevention and control. ACTIVITIES INCLUDE HOTLINES, TOOLS, EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO staff interact and collaborate on a regular basis with ASCO state and regional affiliates, OTHER MEDICAL SPECIALTY AND PROFESSIONAL SOCIETIES, CONGRESS, THE ADMINISTRATION, AND PATIENT ADVOCATE ORGANIZATIONS TO ADVANCE COMMON GOALS RELATED TO CANCER RESEARCH AND QUALITY CARE. THE STATE/REGIONAL AFFILIATE PROGRAM - THE AFFILIATE PROGRAM WAS CREATED IN 1993 TO BETTER ADDRESS ISSUES RAISED IN THE PRACTICE OF ONCOLOGY, AND TO FACILITATE ASCO'S OWN ADVOCACY PROGRAMS. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. ORIGINAL DATA COLLECTION - ASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. EXPENSES $18,436,967. INCLUDING GRANTS OF $0. REVENUE $363,711. MEMBER RELATIONS AND INFORMATION: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 44,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL BIMONTHLY MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO. IT IS THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CUTTING EDGE RESEARCH, BEST PRACTICES STANDARDS, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AND OPPORTUNITIES TO CREATE GROUPS. EXPENSES $4,754,433. INCLUDING GRANTS OF $0. REVENUE $7,936,273. COMMUNICATIONS AND PATIENT INFORMATION: ASCO PROVIDES THE PUBLIC, INCLUDING PATIENTS, THE MEDIA, LEGISLATORS, PHYSICIANS AND OTHER HEALTH CARE PROFESSIONALS, WITH ACCURATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. ASCO HAS A FREE PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET), AVAILABLE TO THE PUBLIC, INCLUDING PATIENTS, THEIR CAREGIVERS, FAMILY MEMBERS AND FRIENDS, THE MEDIA AND HEALTH CARE PROFESSIONALS, THAT PROVIDES UP-TO-DATE INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. THE SITE OFFERS MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES, CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER. IN ADDITION TO ITS WEBSITE CONTENT, ASCO OFFERS PRINTED MATERIALS FOR PATIENTS, SUCH AS: CANCER.NET'S GUIDES TO CANCER (DETAILED GUIDES COVERING SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT,CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR), ASCO ANSWERS FACT SHEETS (A SERIES OF FACT SHEETS THAT PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, QUESTIONS TO ASK THE DOCTOR), BOOKLETS ON TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. ADDITIONAL RESOURCES AVAILABLE ON CANCER.NET. EXPENSES $9,767,302. INCLUDING GRANTS OF $0. REVENUE $166,635. |
| FORM 990, PART VI, SECTION A, LINE 1 |
As of december 31, 2017, the board of directors of asco included 18 members with the right to vote on all matters that come before the board of directors. The board of directors also includes two ex-officio directors without the right to vote, who are the chief executive officer of asco (ceo) and the chair of the board of directors of conquer cancer foundation of the american society of clinical oncology (a non-profit, 501(c)(3) tax-exempt related organization of asco). During the reporting year, the board of directors delegated authority to act on its behalf to the executive committee of the board of directors, consistent with asco's bylaws. The voting members of the executive committee were: the president, president-elect, the chair, the past president, and those directors serving the final year of their present terms. The ceo is a non-voting member of the executive committee. All executive committee members are members of asco's board of directors. The scope of the executive committee's authority is established by asco's bylaws, which provide that, except to the extent specifically prohibited by resolution of the board of directors or otherwise prohibited by law, the executive committee of the board is empowered to make and implement major decisions between board meetings and it may act on items requiring action prior to the next announced board of directors. All actions of the executive committee are reported to the board of directors at the next meeting of the board of directors immediately following the action taken by the executive committee, consistent with asco's bylaws. |
| FORM 990, PART VI, SECTION A, LINE 6 |
ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCOS PROFITS OR EXCESS DUES OR A SHARE OF ASCOS NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS:1. FULL MEMBERS. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. 1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. 2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 70, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. 2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION.3. HONORARY MEMBERS. 3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. 3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. |
| FORM 990, PART VI, SECTION A, LINE 7A |
VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. |
| FORM 990, PART VI, SECTION A, LINE 7B |
ASCOS CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. |
| FORM 990, PART VI, SECTION B, LINE 11 |
AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE SENIOR VICE PRESIDENT AND CHIEF LEGAL OFFICER PRIOR TO FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C |
ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 |
Compensation of chief executive officer (ceo): the duties of the ceo of asco include serving as: the ceo of asco, the ceo of asco's non-profit, 501(c)(3) tax-exempt related organization, conquer cancer foundation of clinical oncology (cc); qopi certification program, llc; the president of asco leasing llc, and the chair of the board of directors of cancerlinq llc. All organizations listed are related organizations of asco. The written employment contract between the ceo and asco addresses compensation of the ceo. The compensation of the ceo was determined by the asco board of directors, following the review and recommendation of the board compensation committee. The compensation committee consulted with independent legal counsel and its independent compensation consultant. The independent compensation consultant collected and reported on comparable market data (including data on comparable compensation for similarly qualified persons in functionally comparable positions at similarly situated organizations) and provided its opinion that the compensation for the ceo was reasonable. The review, recommendation, and determination of the ceo's compensation based on the above described process were most recently undertaken in 2017. Vice President AND Chief Financial Officer: the compensation of the Vice President AND Chief Financial Officer (VP & CFO) was considered and approved by the board compensation committee, after receiving the recommendation of the ceo and consulting with independent legal counsel and its independent compensation consultant as follows. The independent compensation consultant collected and reported on comparable market data (including data on comparable compensation for similarly qualified persons in functionally comparable positions at similarly situated organizations) and provided its opinion that the proposed compensation for the VP & cfo was reasonable. The consideration and approval of the compensation of the VP & cfo based on the above described process were most recently undertaken in 2017. Senior Vice President & Chief Medical Officer: the compensation of the Senior Vice President & Chief Medical Officer (SVP & CMO) was considered and approved by the Board Compensation Committee, after receiving the recommendation of the CEO and consulting with independent legal counsel and its independent compensation consultant as follows. The independent compensation consultant collected and reported on comparable market data (including data on comparable compensation for similarly qualified persons in functionally comparable positions at similarly situated organizations) and provided its opinion that the compensation for the SVP & CMO was reasonable. The written employment contract between the SVP & CMO and ASCO address compensation of the SVP & CMO. The consideration and approval of the compensation of the SVP & CMO based on the above described process was most recently undertaken in 2017. Executive Vice President & Chief Philanthropic Officer of the conquer cancer foundation of clinical oncology (cc): the Executive Vice President & Chief Philanthropic Officer of CC is an employee of asco. The asco board compensation committee considered and approved the compensation of the Executive Vice President & Chief Philanthropic Officer of CC after receiving the recommendation of the ceo and consulting with independent legal counsel and its independent compensation consultant as follows. The independent compensation consultant collected and reported on comparable market data (including data on comparable compensation for similarly qualified persons in functionally comparable positions at similarly situated organizations) and provided its opinion that the compensation of the Executive Vice President & Chief Philanthropic Officer of CC was reasonable. The consideration and approval of the compensation of the Executive Vice President & Chief Philanthropic Officer of CC based on the above described process were most recently undertaken in 2017. Chief Executive Officer of CancerLinQ LLC: the compensation of the Chief Executive Officer of CancerLinQ LLC (CEO of CLQ) was considered and approved by the Board Compensation Committee, after receiving the recommendation of the CEO and consulting with independent legal counsel and its independent compensation consultant as follows. The independent compensation consultant collected and reported on comparable market data (including data on comparable compensation for similarly qualified persons in functionally comparable positions at similarly situated organizations) and provided its opinion that the compensation for the CEO of CLQ was reasonable. The consideration and approval of the compensation of the SVP & CMO based on the above described process was most recently undertaken in 2017. Vice president, integrated media and technology: the compensation of the vice president, integrated media and technology was considered and approved by the board compensation committee, after receiving the recommendation of the ceo and consulting with independent legal counsel and its independent compensation consultant as follows. The independent compensation consultant collected and reported on comparable market data (including data on comparable compensation for similarly qualified persons in functionally comparable positions at similarly situated organizations) and provided its opinion that the compensation of the vice president, integrated media and technology was reasonable. The consideration and approval of the compensation of the vice president, integrated media and technology based on the above described process were most recently undertaken in 2017. |
| FORM 990, PART VI, SECTION C, LINE 19 |
ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE, AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. |
| FORM 990, PART XI, LINE 9 |
GAIN ON INTEREST RATE SWAP $1,289,983 |
| FORM 990 PART IX LINE 11G |
DESCRIPTION:COMMISSIONS TOTAL FEES:4976661 |
| FORM 990 PART IX LINE 11G |
DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1266105 |
| FORM 990 PART IX LINE 11G |
DESCRIPTION:OTHER PROFESSIONAL SERVICES TOTAL FEES:11940341 |
Attach to Form 990 or 990-EZ.